Efficacy of Intralesional Platelet Rich Plasma in Patients of De Quervain's Tenosynovitis

NCT06651034 | Completed

• 1 other identifier: Mayo-2
• Study Type: interventional
• Target: 67
• Locations: 1 country
• Sites: 1

Brief Summary

De Quervain's tenosynovitis (DQT) was originally identified by Swiss surgeon Fritz de Quervain in 1895. It is a condition involving the entrapment of tendons within the first dorsal compartment of the wrist. In DQT, the sheaths surrounding the abductor pollicis longus (APL) and extensor pollicis brevis tendons thicken as they pass through a fibro-osseous tunnel near the radial styloid of the distal wrist. This thickening leads to pain, which worsens with thumb movements and radial or ulnar deviation of the wrist. Traditional treatment methods, such as corticosteroid injections and physical therapy, often provide only temporary relief and may not address the underlying inflammation effectively. Intralesional platelet rich plasma (PRP) therapy has emerged as a promising alternative, utilizing the patient's own growth factors and cytokines to promote healing and reduce inflammation. By investigating the efficacy of intralesional PRP in patients with DQT, this research aims to provide evidence for a minimally invasive treatment option that could enhance recovery times, reduce pain, and improve functional outcomes.

Conditions

De Quervain Tenosynovitis

Outcome Measures

Primary Outcomes (1)

• VAS Pain Score

  The patients were evaluated three weeks after treatment for efficacy. Efficacy was labeled as VAS pain score \< 3 after 3 weeks of intralesional PRP injection.

  3-week

Study Arms (1)

PRP

EXPERIMENTAL

Intralesional Platelet rich plasma

Other: Platelet Rich Plasma

Interventions

Platelet Rich Plasma OTHER

Under aseptic measures, a phlebotomist obtained the blood in vacutainers. Vacutainers was centrifuged and middle zone containing platelet rich plasma was aspirated in a 5 ml disposable syringe. The patient received intralesional injection

PRP

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Either gender,
• Aged between 18 and 60 years
• Presenting with de quervain's tenosynovitis

You may not qualify if:

• Previous surgery or intervention forde quervain's tenosynovitis
• Local skin infection or osteomyelitis
• Pregnant or lactating mothers

Sponsors & Collaborators

• Muhammad Aamir Latif: lead

Study Sites (1)

Department of Orthopedic surgery, KEMU/ Affiliated hospital

Lahore, Pakistan

Location

MeSH Terms

Conditions

De Quervain Disease

Condition Hierarchy (Ancestors)

Tendon Entrapment; Tendinopathy; Muscular Diseases; Musculoskeletal Diseases

Study Officials

• Muhammad Zarak Awais, MBBS

  Department of Orthopedic Surgery, Mayo Hospital, Lahore, Pakistan

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Research Consultant

Model Details: Quasi-experimental study

Study Record Dates

• First Submitted: October 18, 2024
• First Posted: October 21, 2024
• Study Start: September 1, 2021
• Primary Completion: October 30, 2022
• Study Completion: October 30, 2022
• Last Updated: October 21, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)